会计年度:2021-12-31收入分布
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 国际贸易 | 8,397,292,803.02 | 7,088,233,505.18 | 1,309,059,297.84 | 15.59 |
| 合计 | 36,234,414,703.34 | 31,018,238,504.95 | 5,216,176,198.39 | 14.40 |
| 内部抵消 | -540,595,223.00 | -600,054,855.01 | 59,459,632.01 | -11.00 |
| 其他(补充) | 111,704,951.05 | 44,140,572.32 | 67,564,378.73 | 60.48 |
| 其中:原料药 | 750,139,104.02 | 655,206,065.43 | 94,933,038.59 | 12.66 |
| 其中:制剂药 | 2,304,150,032.90 | 641,216,750.32 | 1,662,933,282.58 | 72.17 |
| 其中:中药材加工及饮片 | 513,075,348.97 | 425,429,449.55 | 87,645,899.42 | 17.08 |
| 医药工业 | 3,579,197,578.31 | 1,721,852,265.30 | 1,857,345,313.01 | 51.89 |
| 医药商业 | 24,686,814,593.96 | 22,764,067,017.16 | 1,922,747,576.80 | 7.79 |
|
会计年度:2021-06-30
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 国际贸易 | 4,421,525,886.56 | 3,693,246,155.30 | 728,279,731.26 | 16.47 |
| 合计 | 18,265,345,185.24 | 15,572,046,532.74 | 2,693,298,652.50 | 14.75 |
| 内部抵消 | -261,394,668.87 | -245,340,058.20 | -16,054,610.67 | 6.14 |
| 其他(补充) | 82,552,753.45 | 39,164,634.76 | 43,388,118.69 | 52.56 |
| 其中:原料药 | 322,710,811.36 | 266,764,657.80 | 55,946,153.56 | 17.34 |
| 其中:制剂药 | 1,172,404,029.59 | 314,938,925.86 | 857,465,103.73 | 73.14 |
| 其中:中药材加工及饮片 | 213,964,251.18 | 175,363,588.37 | 38,600,662.81 | 18.04 |
| 医药工业 | 1,709,079,092.13 | 757,067,172.03 | 952,011,920.10 | 55.70 |
| 医药商业 | 12,313,582,121.97 | 11,327,908,628.85 | 985,673,493.12 | 8.00 |
|
会计年度:2020-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 国际贸易 | 12,565,729,608.15 | 10,045,262,568.81 | 2,520,467,039.34 | 20.06 |
| 合计 | 39,311,753,472.09 | 32,512,227,932.59 | 6,799,525,539.50 | 17.30 |
| 内部抵消 | -3,631,134,805.10 | -3,563,012,525.37 | -68,122,279.73 | 1.88 |
| 其他(补充) | 146,755,650.18 | 64,780,630.17 | 81,975,020.01 | 55.86 |
| 其中:原料药 | 841,324,250.61 | 696,935,365.71 | 144,388,884.90 | 17.16 |
| 其中:制剂药 | 2,596,724,579.89 | 598,930,680.40 | 1,997,793,899.49 | 76.94 |
| 其中:中药材加工及饮片 | 498,918,997.28 | 423,387,911.83 | 75,531,085.45 | 15.14 |
| 医药工业 | 3,936,967,827.78 | 1,719,253,957.94 | 2,217,713,869.84 | 56.33 |
| 医药商业 | 26,293,435,191.08 | 24,245,943,301.04 | 2,047,491,890.04 | 7.79 |
|
会计年度:2020-06-30
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 国际贸易 | 7,239,518,050.65 | 6,120,413,051.69 | 1,119,104,998.96 | 15.46 |
| 合计 | 18,809,226,059.46 | 15,689,227,925.40 | 3,119,998,134.06 | 16.59 |
| 内部抵消 | -2,505,305,139.39 | -2,438,236,885.51 | -67,068,253.88 | 2.68 |
| 其他(补充) | 49,482,964.30 | 20,345,108.81 | 29,137,855.49 | 58.88 |
| 其中:原料药 | 502,863,462.67 | 456,156,767.64 | 46,706,695.03 | 9.29 |
| 其中:制剂 | 1,153,931,575.24 | 229,907,354.06 | 924,024,221.18 | 80.08 |
| 其中:中药材加工及饮片 | 224,780,935.14 | 185,247,469.03 | 39,533,466.11 | 17.59 |
| 医药工业 | 1,881,575,973.05 | 871,311,590.73 | 1,010,264,382.32 | 53.69 |
| 医药商业 | 12,143,954,210.85 | 11,115,395,059.68 | 1,028,559,151.17 | 8.47 |
| 中药材加工及饮片 | 224,780,935.14 | 185,247,469.03 | 39,533,466.11 | 17.59 |
|
会计年度:2019-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 国际贸易 | 7,444,877,769.80 | 6,394,584,588.74 | 1,050,293,181.06 | 14.11 |
| 合计 | 35,284,824,314.75 | 28,809,477,758.90 | 6,475,346,555.85 | 18.35 |
| 内部抵消 | -994,131,277.79 | -979,716,410.53 | -14,414,867.26 | 1.45 |
| 其他(补充) | 110,900,673.16 | 45,061,052.93 | 65,839,620.23 | 59.37 |
| 其中：原料药 | 1,005,624,631.63 | 918,319,731.68 | 87,304,899.95 | 8.68 |
| 其中:制剂药 | 3,777,561,554.81 | 626,215,736.23 | 3,151,345,818.58 | 83.42 |
| 医药工业 | 5,176,361,028.59 | 1,836,566,411.15 | 3,339,794,617.44 | 64.52 |
| 医药商业 | 23,546,816,120.99 | 21,512,982,116.61 | 2,033,834,004.38 | 8.64 |
| 制剂药 | 3,777,561,554.81 | 626,215,736.23 | 3,151,345,818.58 | 83.42 |
|
1/9 转到 
